Tazarotene/Betamethasone Dipropionate

Tier C — Watch / trade

Chongqing Huapont Pharm Co., Ltd.

Originator

2015

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：GR, RAR-β, RAR-γ, RAR-α

Indications (approved)：Psoriasis

Regional status

China

Approved

2015-03-27

Japan

Factories producing this API11

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

11 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Tazarotene/Betamethasone Dipropionate?

Approved indications include: Psoriasis.

When does the Tazarotene/Betamethasone Dipropionate patent expire?

No public expiry year is available for Tazarotene/Betamethasone Dipropionate yet; this page updates once verified.

How do I get a quote for Tazarotene/Betamethasone Dipropionate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27